ReviewBest practice & research. Clinical gastroenterology2002
Pancreas and islet cell transplantation.
Review in Best practice & research. Clinical gastroenterology, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Applications of stem cells and bioprinting for potential treatment of diabetes.World journal of stem cells · 2019Review
- Extracellular Matrix and Integrins in Embryonic Stem Cell Differentiation.Biochemistry insights · 2015Review
- Stem cell therapy. Use of differentiated pluripotent stem cells as replacement therapy for treating disease.Science (New York, N.Y.) · 2014Review
- Facilitating physiologic self-regeneration: a step beyond islet cell replacement.Pharmaceutical research · 2006Review
- Current status and prospects for gene and cell therapeutics for type 1 diabetes mellitus.Reviews in endocrine & metabolic disorders · 2003Review
- Gene- and cell-based therapeutics for type I diabetes mellitus.Gene therapy · 2003Review
- Hyperinsulinaemia and hyperglycaemia: possible risk factors of colorectal cancer among diabetic patients.Diabetologia · 2003Review
- Glucagon-like peptide 1 (1-37) converts intestinal epithelial cells into insulin-producing cells.Proceedings of the National Academy of Sciences of the United States of America · 2003Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Currently, for the patient with type 1 diabetes, a definitive treatment without resorting to the use of exogenous insulin can be achieved only with pancreas or islet cell transplantation. These means of restoring beta-cell mass can completely maintain essentially normal long-term glucose homeostasis, although the need for powerful immunosuppressive regimens limits their application to only a subgroup of adult patients. Apart from the shortage of donors that has limited all kinds of transplantation, however, the widespread use of beta-cell replacement has been precluded until recently by the drawbacks associated with both organ and islet cell transplantation. Although the study of recurrence of diabetes has generated attention, the fundamental obstacle to pancreas and islet transplantation has been, and remains, the alloimmune response. With a better elucidation of the mechanisms of alloengraftment achieved during the last 3 years, the stage has been set for further advances.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.